A Better Look at Rheumatoid Arthritis: Using Imaging to Improve Patient Outcomes
This CME/CE-accredited Point-of-Care 201™ program is intended for rheumatologists and other clinicians involved in the management of patients with rheumatoid arthritis (RA). During the video activity, two expert rheumatologists will translate the latest guidelines and clinical trial data into practical recommendations on the use of imaging modalities for the assessment of patients with RA. Topics will include reviews of various imaging techniques, use of ultrasonography to examine synovial inflammation and other changes in RA-affected joints, and application of imaging results to guide shared clinical decision-making with patients.
This activity has been designed to meet the educational needs of rheumatologists and other clinicians involved in the ongoing management of patients with RA.
Upon completion of this activity, participants will be better able to do the following:
- Describe the benefits and limitations of various imaging modalities used to assess patients with RA
- Perform ultrasonography as part of diagnostic workups and ongoing monitoring plans for patients with RA
- Integrate imaging results into shared clinical decision-making and long-term tailoring of RA therapy
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Ralf Thiele, MD, FACR, RhMSUS
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Consultant/Advisor: AbbVie Inc.; Celgene Corporation; Horizon Pharma plc; Iroko Pharmaceuticals, LLC; Pfizer Inc.
Speakers’ Bureau: AbbVie Inc.; Celgene Corporation; Horizon Pharma plc; Novartis AG; Pfizer Inc.
Stock Ownership: AbbVie Inc.; Bristol-Myers Squibb Company; Pfizer Inc.
|Ralf Thiele, MD, FACR, RhMSUS|
Speakers’ Bureau: AbbVie Inc.; Amgen Inc.
Non-faculty: Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education, Dannemiller, and Integritas Communications.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP Credit (Nurse Practitioners)
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Dannemiller the Elsevier Office of Continuing Medical Education. Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 090419. This program is accredited for 0.50 contact hour(s) which includes 0.0 hours of pharmacology.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Dannemiller, Integritas Communications, and Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 AANP
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Non-physician